8-K: Splash Beverage Group Expands CannEpil License to Veterinary Use

Splash Beverage Group has amended its exclusive global license for CannEpil to include veterinary applications, establishing a second regulated pharmaceutical development program.

Summary

• Splash Beverage Group, Inc. (SBEV) has entered into an addendum to its exclusive global license agreement with Argent BioPharma Limited for CannEpil.
• The amendment expands the field of use to include veterinary applications, in addition to human applications.
• A new royalty rate structure has been established: 10% of Net Revenue for veterinary applications and 15% for human applications.
• Several deadlines within the original license agreement have been extended.
• Splash intends to pursue U.S. regulatory approval for veterinary use through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
• Initial veterinary focus will be on companion-animal oncology and chronic pain management, with canine indications as the primary target.
• The company is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it expands the potential market for CannEpil and aligns with strategic diversification, though the extended deadlines and inherent regulatory risks temper the immediate enthusiasm.

Positives

• Expansion of the CannEpil platform into the significant and growing veterinary therapeutics market, creating a second regulated pharmaceutical development program.
• Access to substantial companion-animal oncology and pain-management markets, with projected market values of $3.8 billion by 2030 for veterinary pain management and $900 million to $1.7 billion for veterinary oncology.
• Strategic partnership with an experienced cannabinoid pharmaceutical company to lead veterinary development, bringing proven regulatory and commercialization expertise.
• CannEpil is a pharmaceutical-grade cannabinoid formulation manufactured under EU-GMP standards, with an existing IND application number for its human development program.
• The company is executing a diversified cannabinoid health sciences strategy, encompassing consumer wellness and beverage brands alongside pharmaceutical assets.

Negatives

• The royalty rate for veterinary applications is 10% of Net Revenue, which is a reduction from the 15% for human applications.
• Several deadlines for development and execution have been extended, potentially indicating a slower pace of progress.
• The company acknowledges that there can be no assurance that CannEpil will receive regulatory approval for veterinary use or that commercialization efforts will be successful.

Risks

• The possibility that the license and development efforts for CannEpil do not yield anticipated benefits.
• Challenges in obtaining, maintaining, or protecting intellectual property rights for the licensed product.
• Competition from companies marketing similar products.
• The need to negotiate and execute a joint venture with a strategic collaborator.
• The requirement to comply with contractual obligations for development and commercialization.
• The ability to raise necessary capital for development and working capital needs.
• The need to comply with extensive regulations, including clinical testing, before marketing.
• Evolving regulatory conditions within the cannabinoid and wellness industries.

Future Outlook

Splash Beverage Group is expanding its CannEpil platform into veterinary therapeutics, establishing a second regulated pharmaceutical development program. The company intends to pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways, initially focusing on companion-animal oncology and chronic pain management. A strategic joint venture is being finalized to lead the veterinary development program. The company aims to build a diversified cannabinoid health sciences platform by commercializing international pharmaceutical assets, advancing veterinary and human therapeutics, and developing consumer wellness and beverage brands.

Management Comments

• "Expanding our exclusive CannEpil license into veterinary medicine materially broadens the value of the platform and provides access to significant companion-animal oncology and pain-management markets," said Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group.
• "Cancer and chronic pain affect millions of companion animals, yet treatment options remain limited in many indications. We believe CannEpil's pharmaceutical-grade formulation warrants disciplined evaluation through the FDA veterinary process."
• "Our objective extends well beyond expanding the licensed field of use. We are assembling a world-class development platform around CannEpil by partnering with experienced cannabinoid pharmaceutical executives who have successfully navigated complex regulatory pathways and helped bring cannabinoid medicines to market."
• "We believe pairing differentiated intellectual property with proven scientific and regulatory expertise materially enhances our ability to create long-term shareholder value."
• "Splash is executing a disciplined strategy to build a diversified cannabinoid health sciences platform by commercializing existing international pharmaceutical assets, advancing FDA-regulated veterinary and human therapeutics, and developing innovative cannabinoid consumer wellness and beverage brands for global markets."
• "The expansion of CannEpil into veterinary medicine represents another important milestone in executing that strategy and further positions Splash at the intersection of pharmaceutical innovation and cannabinoid science."

Industry Context

StockSavvy.ai notes that this expansion into veterinary therapeutics aligns with a broader trend of pharmaceutical companies leveraging existing drug platforms for new market segments. The growing companion animal health market, particularly in oncology and pain management, presents a significant opportunity for companies with specialized formulations like CannEpil. This move also positions Splash Beverage Group to capitalize on the increasing acceptance and development of cannabinoid-based treatments across both human and animal health sectors.

Comparison to Industry Standards

• The veterinary pain management market is projected to reach approximately $3.8 billion by 2030, indicating strong growth potential.
• The global veterinary oncology market is estimated between $900 million and $1.7 billion, with continued long-term growth expected.
• Approximately one in four dogs develop cancer during their lifetime, and half of dogs over ten years old develop cancer, highlighting a substantial patient population.
• The U.S. National Cancer Institute estimates about six million dogs are diagnosed with cancer annually in the United States.

Stakeholder Impact

• Shareholders: Potential for increased revenue streams and market capitalization through expansion into the veterinary pharmaceutical market, but also risks associated with development timelines and regulatory approvals.
• Suppliers: Potential for increased demand for raw materials and manufacturing services related to CannEpil for veterinary applications.
• Creditors: The company's ability to raise capital for development and working capital needs will be crucial for meeting its obligations.

Next Steps

• Finalize a strategic joint venture with an established cannabinoid pharmaceutical company to lead CannEpil's veterinary development program.
• Evaluate CannEpil for veterinary applications in companion-animal oncology and chronic pain management.
• Pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways.
• Announce additional details regarding the collaboration in the near future.
• Engage with the FDA and other applicable regulatory authorities to determine actual development timelines, target indications, clinical requirements, and regulatory pathways.

Key Dates

Recommendation

The expansion into the veterinary market is a strategic positive, leveraging an existing asset into a growing sector. However, the extended timelines for key development milestones, the inherent regulatory hurdles for pharmaceutical products, and the need to finalize a joint venture introduce uncertainty. A 'hold' recommendation reflects the potential upside balanced against these significant risks and the need for further clarity on the execution of the veterinary development program.

Keywords

CannEpil, Veterinary Therapeutics, Cannabinoid, Pharmaceutical Development, FDA, Companion Animal, Oncology, Pain Management